ProCE Banner Activity

Extending HCV Care Past Cure to Prevent Reinfection in High-Risk Populations

Clinical Thought

With long-term health and wellness as a framing principle, curing HCV is not the finish line but rather a starting point for a conversation about maintaining wellness, preventing progression of liver disease, addressing harmful drug and alcohol habits, and, of importance, preventing HCV reinfection.

Released: November 30, 2023

Expiration: December 12, 2024

Share

Faculty

Christian B. Ramers

Christian B. Ramers, MD, MPH

Associate Clinical Professor
Division of Infectious Diseases
Department of Medicine
UC San Diego School of Medicine
La Jolla, California
Chief, Population Health
Director, Graduate Medical Education
Family Health Centers of San Diego
San Diego, California

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC

ProCE Banner

Supporters

Gilead

Faculty Disclosure

Primary Author

Christian B. Ramers, MD, MPH

Associate Clinical Professor
Division of Infectious Diseases
Department of Medicine
UC San Diego School of Medicine
La Jolla, California
Chief, Population Health
Director, Graduate Medical Education
Family Health Centers of San Diego
San Diego, California

Christian B. Ramers, MD, MPH, has disclosed that he has received consulting fees from AbbVie and Gilead Sciences; fees for non-CME/CE services from AbbVie, Gilead Sciences, Janssen Therapeutics, and Merck; and funds for research support from Gilead Sciences.